1. Scrip
  2. >>Therapy Areas

Merck KGaA R&D Head: Biomarker Approach 'Further Validated' At ASCO

 
• By Sten Stovall

Luciano Rossetti says Germany's Merck is likely to partner M7824 bifunctional immunotherapy, and go solo with tepotinib.

Tumor marker
Merck KGaA is using biomarkers to select patients for testing Tepotinib and M7824. • Source: Shutterstock

Merck KGAA created an excited stir at ASCO with impressive presentations on its targeted tepotinib and its M7824 TGF-beta trap therapies in non-small cell lung cancer. Its biopharma R&D head tells Scrip the German group wants to develop and commercialize the former on its own, and partner M7824 with a big pharma.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.